FibroGen anemia patent revoked, Teva and Sandoz pave way for generic drug
Teva and Sandoz have successfully challenged FibroGen’s European patent on the anti-anemia drug roxadustat at the European Patent Office, clearing the way for generic alternatives in the EU. The Technical Board...To view the full article, register now.
Already a subscriber? Click here to view full article